CG Invites (Co-CEOs Chung In-chul and Oh Su-yeon), a frontrunner in digital genomics-driven drug development, announced groundbreaking preclinical results for their personalized cancer immunotherapy vaccine on the 11th.

Cancer vaccines epitomize personalized medicine, harnessing tumor-specific antigens to activate the patient's immune system for targeted malignant cell elimination. With their exceptional safety profile and minimal adverse effects, these immunotherapeutics are positioned as leading candidates for next-generation cancer treatment. The field has garnered global attention following Moderna's encouraging clinical outcomes for their melanoma vaccine, presented at the American Society of Clinica